 REDWOOD CITY, Calif., Nov. 12, 2020 GLOBE NEWSWIRE -- Graybug Vision, Inc. Nasdaq: GRAY, a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today provided an update on recent corporate developments and reported financial results for the three and nine months ended September 30, 2020. 